Evaluating ANI Pharmaceuticals: Insights From 5 Financial Analysts

ANI Pharmaceuticals ANIP has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.

The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 5 0 0 0 0
Last 30D 1 0 0 0 0
1M Ago 0 0 0 0 0
2M Ago 3 0 0 0 0
3M Ago 1 0 0 0 0

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $77.8, with a high estimate of $83.00 and a low estimate of $72.00. Observing a 9.19% increase, the current average has risen from the previous average price target of $71.25.

price target chart

Interpreting Analyst Ratings: A Closer Look

A clear picture of ANI Pharmaceuticals's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target
Vamil Divan Guggenheim Maintains Buy $77.00 -
Vamil Divan Guggenheim Raises Buy $77.00 $70.00
Oren Livnat HC Wainwright & Co. Raises Buy $83.00 $73.00
Gregory Fraser Truist Securities Raises Buy $80.00 $72.00
Gregory Fraser Truist Securities Raises Buy $72.00 $70.00

Key Insights:

  • Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to ANI Pharmaceuticals. This offers insight into analysts' perspectives on the current state of the company.
  • Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of ANI Pharmaceuticals compared to the broader market.
  • Price Targets: Analysts provide insights into price targets, offering estimates for the future value of ANI Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.

Capture valuable insights into ANI Pharmaceuticals's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.

Stay up to date on ANI Pharmaceuticals analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

About ANI Pharmaceuticals

ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.

ANI Pharmaceuticals: Delving into Financials

Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.

Revenue Growth: ANI Pharmaceuticals's remarkable performance in 3 months is evident. As of 31 December, 2023, the company achieved an impressive revenue growth rate of 39.71%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.

Net Margin: ANI Pharmaceuticals's net margin excels beyond industry benchmarks, reaching 0.57%. This signifies efficient cost management and strong financial health.

Return on Equity (ROE): ANI Pharmaceuticals's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.17% ROE, the company effectively utilizes shareholder equity capital.

Return on Assets (ROA): ANI Pharmaceuticals's ROA excels beyond industry benchmarks, reaching 0.08%. This signifies efficient management of assets and strong financial health.

Debt Management: ANI Pharmaceuticals's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.66.

Understanding the Relevance of Analyst Ratings

Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.

Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst RatingsBZI-AAR
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!